Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of SN1011 in Healthy Subjects
NCT04041544Phase 1Unknown
- Sponsor
- SinoMab BioScience Limited
- Start
- Aug 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing SN1011 with SN1011 placebo (2 arms). Primary endpoints: Incidence and severity of adverse events and Clinically significant changes from baseline in physical examinations. Status: unknown.
02
Drugs
ever001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04041544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041544.